Chemotherapy versus transplants for acute myelogenous leukemia in second remission

Leukemia

Volumn 10, Issue 1, 1996, Pages 13-19

  Gale, R P ^a   Horowitz, M M ^b   Rees, J K H ^c   Gray, R G ^d   Oken, M M ^e   Estey, E H ^f   Kim, K M ^g   Zhang, M J ^b   Ash, R C ^b   Atkinson, K ^h   Champlin, R E ^f   Dicke, K A ⁱ   Gajewski, J L ^f   Goldman, J M ^j   Helbig, W ^k   Henslee Downey, P J ^l   Hinterberger, W ^m   Jacobsen, N ⁿ   Keating, A ^o   Klein, J P ^b   Marmont, A M ^p   Prentice, H G ^q   Reiffers, J ^r   Rimm, A A ^s   Rowlings, P A ^b   Sobocinski, K A ^b   Speck, B ^t   Wingard, J R ^u   Bortin, M M ^b   more..

^a Salick Health Care Inc   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d RADCLIFFE INFIRMARY   (United Kingdom)

^e ABBOTT NORTHWESTERN HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g Eastern Cooperative Oncology Group   (United States)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ Arlington Cancer Center   (United States)

^j HAMMERSMITH HOSPITAL   (United Kingdom)

^k UNIVERSITY OF LEIPZIG   (Germany)

^l UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m DANUBE HOSPITAL   (Austria)

ⁿ University of Copenhagen   (Denmark)

^o UNIVERSITY HEALTH NETWORK   (Canada)

^p UNIVERSITY OF GENOA   (Italy)

^q ROYAL FREE HOSPITAL   (United Kingdom)

^r BORDEAUX UNIVERSITY HOSPITAL   (France)

^s CASE WESTERN RESERVE UNIVERSITY   (United States)

^t UNIVERSITY HOSPITAL BASEL   (Switzerland)

^u EMORY UNIVERSITY   (United States)

more..

Author keywords

Acute myelogenous leukemia; Bone marrow transplant; Chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 9044235781     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Champlin RE, Gale RP. Acute myelogenous leukemia: Recent advances in therapy. Blood 1987; 69: 1551-1562.
2. Clift RA et al. The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243-258.
3. Gale RP, Horowitz MM, Biggs JC. Transplant or chemotherapy in acute myelogenous leukemia. Lancet 1989; 1: 1119-1122
4. European Group for Bone Marrow Transplantation: Working Party on Leukemia. Allogeneic bone marrow transplants of leukemia in Europe. Lancet 1988; i: 1379-1382.
5. Begg CB et al. A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute myelogenous leukemia. J Clin Oncol 1984; 2: 369-378.
6. Gale RP, Horowitz MM. How best to analyze new strategies in bone marrow transplantation. Bone Marrow Transplant 1990; 6: 357-359.
7. Rees JKH, Swirsky D, Gray RG, Hayhoe FGJ. Principal results of the Medical Research Council's 8th Acute Myeloid Leukaemia Trial. Lancet 1986; 331: 1236-1241.
8. Rees JKH, Gray RG. Post remission therapy in acute myeloid leukaemia: The Medical Research Council experience. Bone Marrow Transplant 1989; 4 (suppl. 3): 70-72
9. Oken MM et al. Maintenance low-dose Ara-C improves complete remission duration from salvage induction therapy for refractory acute myeloid leukemia. Proc Am Soc Clin Oncol 1991; 10: 220.
10. Keating MJ et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071-1080.
11. Estey EH et al. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. J Clin Oncol 1984; 2: 102-106.
12. Estey EH et al. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 1983; 67: 389-390.
13. Kantarjian HM et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986; 81: 387-394.
14. Estey E et al. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987; 1: 580-583.
15. Clift R, Goldman JM, Gratwohl A, Horowitz MM. Proposals for standardized reporting of bone marrow transplantation for leukemia. Bone Marrow Transplant 1989; 4: 445-448.
16. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972; 34: 187-220.
17. Mantel N, Byar D. Evaluation of response-time data involving transient status: an illustration using heart-transplant data. JAMA 1974; 69: 81-86.
18. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991; 7 (suppl. 3): 9-13.
19. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481 and 562-563.
20. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometriks 1982; 69: 133-143.
21. Keiding N, Gill RD. Random truncation models and Markov processes. Ann Statist 1990; 18: 582-602.
22. Ringden O et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early ieukemia? Blood 1993; 81: 1094-1101.
23. Keating A et al. Comparison of HLA-identical siblings and autologous bone marrow transplants for acute myelogenous leukemia. Blood 1994; 84 (suppl. 1): 201a.
24. Wells RJ et al. Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. Leukemia 1994; 8: 1626-1630.
25. Appelbaum FR, Clift RA, Buckner CD. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after 1st relapse. Blood 1983; 61: 949-953.
26. Clift RA et al. Allogeneic marrow transplantation during untreated 1st relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 1723-1729.